March 29, 2021

Online Nomogram is an important clinical tool for surgeons and oncologists in the prognostic evaluation of patients with sarcomas

Nomogram is a diagram that represents the relations between three or more variable quantities through multiple scales. Sarculator is an online validated nomogram that predicts overall survival […]
September 3, 2020

Study suggests correlation between the use of vitamin D in the pretreatment and decreased risk of immune checkpoint inhibitor‐induced colitis

Immune checkpoint inhibitors can cause serious immune-related adverse events A study released in June of this year by Grover et al in the Journal of Cancer […]
August 6, 2020

COVID – 19 and the factors that influence clinical outcomes in patients with cancer

A study recently published in The Lancet sought to understand the course of COVID-19 and the factors that influence clinical outcomes in patients with cancer The […]
July 21, 2020

KEYNOTE-048 results show that pembrolizumab + chemotherapy was superior in overall survival versus EXTREME in the first line for patients with head and neck cancer

Post hoc analysis of the CPS <1 and CPS 1-19 (CPS: combined positive score) subgroups of the phase III KEYNOTE-048 trial was presented at AACR 2020 […]
April 27, 2020

Apixaban to prevent venous thromboembolism in patients with cancer

CARAVAGGIO study: oral apixaban was not inferior to dalteparin A study published in the New England Journal of Medicine evaluated the use of apixaban – an […]
December 5, 2019

Innovative technique is able to identify aggressive tumors

Over the past decade, next-generation sequencing (NGS) platforms have become widespread and become one of the foundations of Precision Oncology. However, multiplexing multiple samples in parallel […]
July 8, 2019

FDA approves the first chemoimmunotherapy regimen for patients with diffuse large B-cell lymphoma

On June 10, the Food and Drug Administration (FDA) approved Polivy® (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab (a combination known as BR) for the […]
May 21, 2019

EMA revoked olaratumab approval for treatment soft tissue sarcoma

In 23 to 26 April 2019, the Committee for Medicinal Products for Human Use (CHMP) completed its assessment of the results of the ANNOUNCE study, which […]
May 8, 2019

I-PREDICT Study reported an important benefit for personalized combination therapies

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies. Tumor complexity and heterogeneity […]